Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

L. Elizabeth Budde, Matthew Matasar, Laurie H. Sehn, Sarit E. Assouline, John Kuruvilla, Ian W. Flinn, Sung-Soo Yoon, Francesc Bosch, Daniel Greenwald, Norma C. Gutierrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett

Blood (2024) 144 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2024-197902

Published: 2024

Journal Articles

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Blood (2024) 144 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2024-194612

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Blood (2024) 144 (Supplement 1): 4395.

https://doi.org/10.1182/blood-2024-201269

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab

Blood (2024) 144 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2024-204593

Published: 2024

Journal Articles

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Blood (2024) 144 (Supplement 1): 3109.

https://doi.org/10.1182/blood-2024-207895

Published: 2024

Journal Articles

Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo

Almudena Cabero Martínez, Ana García Bacelar, Begoña Mendibil Esquisabel, Javier Nuñez Cespedes, Ana Jiménez Ubieto, Eukene Gainza Gonzalez, Elena Perez Ceballos, Beatriz De La Cruz, Ana Garcia Noblejas, Paula Fernández-Caldas, Norma C. Gutierrez, Blanca Sánchez-González, Rocío Figueroa Mora, Alberto Lopez Garcia, Daniel García Belmonte, Maria Sanchez de Castro, Estefania Cerezo Velasco, Xabier Martin Martitegui, Hugo Daniel Luzardo Henríquez, Jordina Rovira, Luis Antonio Lopez Gomez, Jackeline Solano, Ana Torres Tienza, Maria Stefania Infante, Raquel Santiago Alonso, Raquel Del Campo, Dunia De Miguel Llorente, Alicia Roldán-Pérez, Emilia Pardal, Beatriz Gonzalez Mena, Miguel Ángel Rodríguez Gil, Nazaret Domínguez Velasco, Albert Blanco Juan, Maria Alejandra Blum Dominguez, Javier López Marin, María Peñarrubia-Ponce, Mariana Bastos-Oreiro, Alejandro Martín García-Sancho

Blood (2024) 144 (Supplement 1): 1708.

https://doi.org/10.1182/blood-2024-198904

Published: 2024

Journal Articles

Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Blood (2024) 144 (Supplement 1): 4390.

https://doi.org/10.1182/blood-2024-197940

Published: 2024

Journal Articles

Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Blood (2024) 144 (Supplement 1): 3374.

https://doi.org/10.1182/blood-2024-205453

Published: 2024

Journal Articles

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Blood (2024) 143 (7): 597–603.

https://doi.org/10.1182/blood.2023022083

Published: 2024

Includes: Supplemental data

Journal Articles

Early Identification of Very High Risk Patients with Diffuse Large B Cell Lymphoma (DLBCL) By PET-CT

Blood (2023) 142 (Supplement 1): 4511.

https://doi.org/10.1182/blood-2023-186952

Published: 2023

Journal Articles

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 646.

https://doi.org/10.1182/blood-2023-186411

Published: 2023

Journal Articles

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Blood (2023) 142 (Supplement 1): 645.

https://doi.org/10.1182/blood-2023-182964

Published: 2023

Journal Articles

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Blood (2022) 140 (Supplement 1): 3753–3755.

https://doi.org/10.1182/blood-2022-157729

Published: 2022

Journal Articles

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Catarina Maia, Noemi Puig, Cristina Pérez Ruiz, Maria Teresa Cedena Romero, Camila Guerrero, Marta Larrayoz, Cirino Botta, Norma C. Gutierrez, María José Calasanz, Maria Luisa Martin-Ramos, Miguel Hernández, Laura Rosinol Dachs, Esther González Garcia, Felipe De Arriba, Albert Oriol, Veronica Gonzalez-Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella Mesa, Rafael Rios, Ricarda Belen Garcia Sanchez, Jose Maria Arguiñano PEREZ, Adrian Alegre, Jesus Martin, María del Carmen Couto Caro, Maria Casanova, Mario Arnao Herraiz, Ernesto Pérez, Sebastián Garzón López, Marta Sonia Gonzalez Perez, Guillermo Martín-Nuñez, Adriana Rossi, Morton Coleman, Cristina Encinas, Ana M. Vale, Ana Isabel Teruel, María Cortés Rodríguez, Jose A. Martinez-Climent, Juan-José Lahuerta, Joan Bladé Creixenti, Ruben Niesvizky, Jesús San-Miguel, Maria-Victoria Mateos, Bruno Paiva

Blood (2022) 140 (Supplement 1): 4200–4203.

https://doi.org/10.1182/blood-2022-163058

Published: 2022

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Blood (2022) 140 (Supplement 1): 292–294.

https://doi.org/10.1182/blood-2022-159606

Published: 2022

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2021) 138 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2021-148423

Published: 2021

Journal Articles

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Blood (2021) 138 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2021-147937

Published: 2021

Journal Articles

A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM)

Blood (2021) 138 (Supplement 1): 1596.

https://doi.org/10.1182/blood-2021-145968

Published: 2021

Journal Articles

Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

Franck Morschhauser, Mark Bishton, Toby A. Eyre, Emmanuel Bachy, Guillaume Cartron, Loïc Ysebaert, Sabela Bobillo, Norma C. Gutierrez, L. Elizabeth Budde, Christopher P. Fox, Andrea Knapp, Manejeh Yaqub, Michael C. Wei, Carol O'Hear, Haocheng Li, Enkhtsetseg Purev, William Townsend

Blood (2021) 138 (Supplement 1): 129.

https://doi.org/10.1182/blood-2021-145694

Published: 2021

Journal Articles

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Blood (2021) 137 (1): 49–60.

https://doi.org/10.1182/blood.2020006731

Published: 2021

Includes: Supplemental data

NARROW

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo

Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Early Identification of Very High Risk Patients with Diffuse Large B Cell Lymphoma (DLBCL) By PET-CT

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM)

Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only